본문 바로가기
KERD
논문KCI 등재

Differences in the patterns and outcomes of enhanced viral replication between hepatitis C virus and hepatitis B virus in patients with hepatocellular carcinoma during transarterial chemolipiodolization

박정화|권정현|최종영|장정원|송도선|김희언|윤승규|송명준|배시현|유선홍|유찬란|성필수
대한간학회 (The korean Association for the Study of the Liver)|2011.12|Clinical and Molecular Hepatology|제17권 제4호|pp. 299-306

1

조회

0

다운로드

10

인용

0

참고문헌

키워드

Hepatocellular carcinomaHepatitis C virusTransarterial chemotherapyViral replication

초록

Background/Aims: Enhanced replication of hepatitis C virus (HCV) is well described in the setting of moderate to severe immunosuppression. The aims of this retrospective study were to determine the incidence of enhanced HCV replication in hepatocellular carcinoma (HCC) patients undergoing transarterial chemolipiodolization (TACL) and to identify the factors associated with enhanced replication of HCV. The clinical pattern of enhanced HCV replication was compared with hepatitis B virus (HBV) reactivation during TACL. Methods: This study enrolled 49 anti-HCV-seropositive patients who were diagnosed with HCC between January 2005 and December 2010 and who underwent TACL using epirubicin and/or cisplatin with consecutive HCV RNA copies checked. For comparison, 46 hepatitis B surface antigen1-positive patients with HCC who were treated with TACL were also enrolled. The frequency, associated factors, and clinical outcomes of enhanced HCV replication were analyzed and compared with those of HBV reactivation during TACL. Results: Enhanced replication of HCV occurred in 13 (26.5%) of the 49 anti-HCV-seropositive patients during TACL. Of these 13 patients, 4developed hepatitis, but none of the subjects developed decompensation due to the hepatitis. No significant clinical factors for enhanced HCV replication during TACL were found. Compared with HBV reactivation, the frequency of hepatitis attributed to enhanced HCV replication was significantly lower than that for HBV reactivation (8.2% vs. 23.9%,P=0.036). Conclusions: TACL can enhance HCV replication; however, the likelihood of hepatitis and decompensation stemming from enhanced HCV replication was lower than that for HBV reactivation in patients undergoing TACL.

Abstract

Background/Aims: Enhanced replication of hepatitis C virus (HCV) is well described in the setting of moderate to severe immunosuppression. The aims of this retrospective study were to determine the incidence of enhanced HCV replication in hepatocellular carcinoma (HCC) patients undergoing transarterial chemolipiodolization (TACL) and to identify the factors associated with enhanced replication of HCV. The clinical pattern of enhanced HCV replication was compared with hepatitis B virus (HBV) reactivation during TACL. Methods: This study enrolled 49 anti-HCV-seropositive patients who were diagnosed with HCC between January 2005 and December 2010 and who underwent TACL using epirubicin and/or cisplatin with consecutive HCV RNA copies checked. For comparison, 46 hepatitis B surface antigen1-positive patients with HCC who were treated with TACL were also enrolled. The frequency, associated factors, and clinical outcomes of enhanced HCV replication were analyzed and compared with those of HBV reactivation during TACL. Results: Enhanced replication of HCV occurred in 13 (26.5%) of the 49 anti-HCV-seropositive patients during TACL. Of these 13 patients, 4developed hepatitis, but none of the subjects developed decompensation due to the hepatitis. No significant clinical factors for enhanced HCV replication during TACL were found. Compared with HBV reactivation, the frequency of hepatitis attributed to enhanced HCV replication was significantly lower than that for HBV reactivation (8.2% vs. 23.9%,P=0.036). Conclusions: TACL can enhance HCV replication; however, the likelihood of hepatitis and decompensation stemming from enhanced HCV replication was lower than that for HBV reactivation in patients undergoing TACL.

참고문헌 (33)

  1. Afdhal NH, "The natural history of hepatitis C", Semin Liver Dis, 24(2), pp.3~8 (2004)
  2. Bowen DG, "Mutational escape from CD8+ T cell immunity: HCV evolution, from chimpanzees to man", J Exp Med, 201, pp.1709~1714 (2005)
  3. Zuckerman E, "Liver dysfunction in patients infected with hepatitis C virus undergoing chemotherapy for hematologic malignancies", Cancer, 83, pp.1224~1230 (1998)
  4. Melichar B, "Effect of irinotecan on the phenotype of peripheral blood leukocyte populations in patients with metastatic colorectal cancer", Hepatogastroenterology, 49, pp.967~970 (2002)
  5. Vento S, "Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus", Lancet, 347, pp.92~93 (1996)
  6. Brown DB, "Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy", J Vasc Interv Radiol, 17, pp.225~232 (2006)
  7. Llovet JM, "Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial", Lancet, 359, pp.1734~1739 (2002)
  8. Lo CM, "Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma", Hepatology, 35, pp.1164~1171 (2002)
  9. Yoshikawa M, "A randomized trial of intrahepatic arterial infusion of 4'-epidoxorubicin with Lipiodol versus 4'-epidoxorubicin alone in the treatment of hepatocellular carcinoma", Cancer Chemother Pharmacol, 33, pp.149~152 (1994)
  10. Jang JW, "Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma", J Hepatol, 41, pp.427~435 (2004)
  11. Usuda S, "Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the preS2-region product", J Virol Methods, 80, pp.97~112 (1999)
  12. Lok AS, "Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study", Gastroenterology, 100, pp.182~188 (1991)
  13. Yeo W, "Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors", J Med Virol, 62, pp.299~307 (2000)
  14. Bruix J, "Prognostic assessment and evaluation of the benefits of treatment", J Clin Gastroenterol, 35(2), pp.138~142 (2002)
  15. Firpi RJ, "Management of viral hepatitis in hematologic malignancies", Blood Rev, 22, pp.117~126 (2008)
  16. Xunrong L, "Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy-pathogenesis and management", Rev Med Virol, 11, pp.287~299 (2001)
  17. Dai MS, "Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration", Liver Int, 24, pp.540~546 (2004)
  18. Idilman R, "Lamivudine prophylaxis in HBV carriers with haematooncological malignancies who receive chemotherapy", J Antimicrob Chemother, 55, pp.828~831 (2005)
  19. Jang JW, "A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization", HEPATOLOGY, 43, pp.233~240, JOHN WILEY & SONS INC
  20. Lau GK, "Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy", Gastroenterology, 125, pp.1742~1749 (2003)
  21. Li YH, "Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma", Cancer, 106, pp.1320~1325 (2006)
  22. Yeo W, "virus reactivation during chemotherapy in breast cancer patients", Breast Cancer Res Treat, 88, pp.209~215 (2004)
  23. Rumi MG, "Hepatitis C reactivation in patients with chronic infection with genotypes 1b and 2c: a retrospective cohort study of 206 untreated patients", Gut, 54, pp.402~406 (2005)
  24. Pitini V, "HCV genotype 2 as a risk factor for reactivation in patients with B-cell lymphoma undergoing rituximab combination chemotherapy", Br J Haematol, 150, pp.116~118 (2010)
  25. Pham TN, "Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C", J Virol, 78, pp.5867~5874 (2004)
  26. Radkowski M, "Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C", Hepatology, 41, pp.106~114 (2005)
  27. Gerlach JT, "Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C", Gastroenterology, 117, pp.933~941 (1999)
  28. Nascimbeni M, "Kinetics of CD4+ and CD8+ memory T-cell responses during hepatitis C virus rechallenge of previously recovered chimpanzees", J Virol, 77, pp.4781~4793 (2003)
  29. Shoukry NH, "Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection", J Exp Med, 197, pp.1645~1655 (2003)
  30. Urbani S, "Virus-specific CD8+ lymphocytes share the same effector-memory phenotype but exhibit functional differences in acute hepatitis B and C", J Virol, 76, pp.12423~12434 (2002)
  31. Thimme R, "Determinants of viral clearance and persistence during acute hepatitis C virus infection", J Exp Med, 194, pp.1395~1406 (2001)
  32. Lechner F, "Analysis of successful immune responses in persons infected with hepatitis C virus", J Exp Med, 191, pp.1499~1512 (2000)
  33. Farci P, "The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies", Science, 288, pp.339~344 (2000)

관련 논문AI추천

Preemptive antiviral therapy with entecavir can reduce acute deterioration of hepatic function following transarterial chemoembolization권정현, 유선홍, 장보현, 장정원, 정승민, 최종영대한간학회 · Clinical and Molecular Hepatology2016 · 제22권 제4호Reactivation of Hepatitis C Virus and Its Clinical Outcomes in Patients Treated with Systemic Chemotherapy or Immunosuppressive Therapy양현, 남희철, 배시현, 성필수, 송병주, 윤승규, 이승원, 이종욱, 이혜민, 장보현, 장정원, 최종영, 한남익, 황서원거트앤리버 소화기연관학회협의회 · Gut and Liver2017 · 제11권 제6호Antiviral Therapy in Patients after Treatment for Hepatitis C-Related Hepatocellular Carcinoma백승운, 신수린, 이종철, Byung Chul Yoo, Geum-Youn Gwak, Joon Hyoek Lee, Kwang Cheol Koh, Moon Seok Choi거트앤리버 소화기연관학회협의회 · Gut and Liver2011 · 제5권 제1호Hepatic Failure Caused by Reactivation of YMDD Mutants Occurring during Preemptive Lamivudine Therapy계철승, 배시현, 윤승규, 장정원, 최종영, Chan Ran You, Jae Ki Choi거트앤리버 소화기연관학회협의회 · Gut and Liver2010 · 제4권 제2호Clinical outcomes of patients with a single hepatocellular carcinoma less than 5 cm treated with transarterial chemoembolization김부성, 김상균, 김영석, 김용권, 김용재, 김홍수, 박수연, 백민영, 유정주, 이세환, 장재영, 정승원, 정신옥, 조영덕, 차상우대한내과학회 · The Korean Journal of Internal Medicine2019 · 제34권 제6호Bi-monthly hepatic arterial infusion chemotherapy as a novel strategy for advanced hepatocellular carcinoma in decompensated cirrhotic patientsAkira Mitoro, Akitoshi Douhara, Hideto Kawaratani, Hiroaki Takaya, Hitoshi Yoshiji, Junichi Yamao, Kei Moriya, Koh Kitagawa, Kosuke Kaji, Masanori Furukawa, Naotaka Shimozato, Shinya Sato, Soichiro Saikawa, Tadashi Namisaki, Takemi Akahane, Yasuhiko Sawada대한간학회 · Clinical and Molecular Hepatology2019 · 제25권 제4호

이 간행물의 다른 논문 (8건)

Virologic response is not durable after adefovir discontinuation in lamivudine-resistant chronic hepatitis B patients김지훈, 변관수, 서연석, 임형준, 엄순호, 연종은, 정은석, 유호상, 김정한, 정영걸, 이광균pp. 261-267Pretreatment serum HBsAg-to-HBV DNA ratio predicts a virologic response to entecavir in chronic hepatitis B이동호, 신철민, 김여명, 김종엽, 김진욱, 민보영, 송준창, 김나영, 정숙향, 황진혁, 이상협pp. 268-273Socioeconomic costs of liver disease in Korea현경래, 이선미, 정우진pp. 274-291Chemical pleurodesis for the management of refractory hepatic hydrothorax in patients with decompensated liver cirrhosis조용균, 박동일, 김병익, 손정일, 김홍주, 박정호, 전우규, 이우진pp. 292-298Clinical features of acute viral hepatitis B in Korea: a multi-center study서연석, 권소영, 김승업, 백순구, 변관수, 고순영, 최혜진, 김영석, 김정한, 이창홍, 김지훈, 정재연, 최원혁, 김태엽, 권오상pp. 307-312
원문 보기